Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 409-414

  Quaglino, P ^a   Marenco, F ^a   Osella Abate, S ^a   Cappello, N ^b   Ortoncelli, M ^a   Salomone, B ^a   Fierro, M T ^a   Savoia, P ^a   Bernengo, M G ^a  

^a First Dermatologic Division   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Autoimmune diseases; Melanoma; Multivariate analyses; Prognosis; Vitiligo

Indexed keywords

INTERFERON; INTERLEUKIN 2; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VITILIGO; EVALUATION; FOLLOW UP; HOSPITAL; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL;

ADULT; AGED; AUTOIMMUNE DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HOSPITALS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VITILIGO; YOUNG ADULT;

EID: 77951923670     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp325     Document Type: Article

References (35)

1. Koh HK, Sober AJ, Nakagawa H et al. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983; 9: 696-708.
2. Barrière H, Litoux P, Le Lay M et al. Cutaneous achromia and malignant melanoma. Ann Dermatol Venereol 1984; 111: 991-996.
3. Bystryn JC, Rigel D, Friedman RJ et al. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-1055.
4. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991; 183: 239-245.
5. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995; 131: 314-318.
6. Garbelli S, Mantovani S, Palermo B et al. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res 2005; 18: 234-242.
7. Lindelöf B, Hedblad MA, Sigurgeirsson B. On the association between vitiligo and malignant melanoma. Acta Derm Venereol 1998; 78: 483-484.
8. Goldman L, Wilson RG, Glasgow R et al. Perilesional leucoderma in metastatic melanoma. The use of the Wood's light for early detection of this rare reaction. Acta Derm Venereol 1967; 47: 369-372.
9. Arpaia N, Cassano N, Vena GA. Regressing cutaneous malignant melanoma and vitiligo-like depigmentation. Int J Dermatol 2006; 45: 952-956.
10. Daneshpazhooh M, Shokoohi A, Dadban A et al. The course of melanomaassociated vitiligo: report of a case. Melanoma Res 2006; 16: 371-373.
11. Nordlund JJ, Kirkwood JM, Forget BM et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
12. Guillot B, Blazquez L, Bessis D et al. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004; 208: 49-54.
13. Luiten RM, Kueter EW, Mooi W et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23: 8978-8991.
14. Phan GQ, Attia P, Steinberg SM et al. Factors associated with response to highdose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
15. Boasberg PD, Hoon DS, Piro LD et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-2663.
16. Chianese-Bullock KA, Woodson EM, Tao H et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005; 28: 412-419.
17. Hartmann A, Bedenk C, Keikavoussi P et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6(12): 1053-1059.
18. Richards JM, Mehta N, Ramming K et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
19. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-84.
20. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
21. Balch CM, Buzaid AC, Atkins MB et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88(6): 1484-1491.
22. Bernengo MG, Quaglino P, Cappello N et al. Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: a multivariate analysis of disease-free survival in 3,174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. G Ital Dermatol Venereol 2005; 140: 191-200.
23. Quaglino P, Borgognoni L, Bottoni U et al. Italian guidelines for staging and follow-up of stage I-II cutaneous melanoma patients. G Ital Dermatol Venereol 2007; 142: 41-47.
24. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol 1977; 97: 255-261.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 475-480.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
27. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
28. Taïeb A, Picardo M. VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
29. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360(2): 160-169.
30. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007; 73: 149-156.
31. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
32. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
33. Le Poole IC, Luiten RM. Autoimmune etiology of generalised vitiligo. Curr Dir Autoimmun 2008; 10: 227-243.
34. Mandelcorn-Monson RL, Shear NH, Yau E et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121: 550-556.
35. Becker JC, Guldberg P, Zeuthen J et al. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999; 113: 1033-1038.